A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
← catalyst calendarSponsored by Sanofi (industry) · SNY — their whole pipeline →. With Kymera Therapeutics, Inc..
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
70actual
Sites
52
Countries
Canada, Chile, Germany +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision. Not related to safety concern.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-29 | actual | When the study began enrolling |
| Primary completion | 2025-10-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-12 | actual | The whole study's end, after follow-up |
| First posted | 2023-09-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: SAR444656 (KT-474)
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in total abscess and inflammatory nodule (AN) count
measured Week 16
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed